Payment overview · 2025
General Payments
$632.86
31 reported records · 11 companies
Healthcare provider profile · identity verified
Rajesh V Dalal, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAKE JACKSON, TX · NPI 1316928021
Verified facts
What the public records show
CMS Open Payments records show Rajesh V Dalal, MD received $632.86 in general payments during 2025 across 31 reported records.
AstraZeneca Pharmaceuticals LP accounted for 32.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Prolia, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $206.62 | 32.6% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $98.80 | 15.6% | 5 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $77.07 | 12.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $58.75 | 9.3% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.89 | 8.2% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $50.30 | 8.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.83 | 3.3% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $18.81 | 3.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.55 | 2.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.01 | 2.7% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $14.23 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $632.86 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $178.23 | 8 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $77.07 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $66.75 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $58.73 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $58.73 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $51.89 | 3 | 2025 |
Source payment records
|
|||||
| MAKO Normalized: mako |
Device | Stryker Corporation | $50.30 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $40.07 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $40.07 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.27 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 99 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 50 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 46 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 48 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
48 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
99 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1438 | 440 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1120 | 321 |
| Losartan Potassium | Losartan Potassium | 906 | 288 |
| Amlodipine Besylate | Amlodipine Besylate | 662 | 201 |
| Gabapentin | Gabapentin | 528 | 190 |
| Metoprolol Succinate | Metoprolol Succinate | 496 | 139 |
| Spironolactone | Spironolactone | 496 | 174 |
| Montelukast Sodium | Montelukast Sodium | 426 | 154 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 415 | 128 |
| Carvedilol | Carvedilol | 366 | 107 |
| Trazodone Hcl | Trazodone Hcl | 360 | 109 |
| Famotidine | Famotidine | 353 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 342 | 129 |
| Tamsulosin Hcl | Tamsulosin Hcl | 287 | 88 |
| Clopidogrel | Clopidogrel Bisulfate | 284 | 96 |
| Eliquis | Apixaban | 282 | 58 |
| Furosemide | Furosemide | 251 | 89 |
| Ezetimibe | Ezetimibe | 248 | 83 |
| Duloxetine Hcl | Duloxetine Hcl | 231 | 61 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 230 | 77 |
| Simvastatin | Simvastatin | 218 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 215 | 69 |
| Metformin Hcl | Metformin Hcl | 211 | 67 |
| Sertraline Hcl | Sertraline Hcl | 203 | 72 |
| Finasteride | Finasteride | 191 | 57 |
| Tramadol Hcl | Tramadol Hcl | 190 | 58 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 187 | 159 |
| Allopurinol | Allopurinol | 186 | 53 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 184 | 52 |
| Memantine Hcl | Memantine Hcl | 177 | 54 |
| Glimepiride | Glimepiride | 176 | 54 |
| Omeprazole | Omeprazole | 176 | 52 |
| Metformin Hcl Er | Metformin Hcl | 172 | 64 |
| Bupropion Xl | Bupropion Hcl | 171 | 53 |
| Hydralazine Hcl | Hydralazine Hcl | 160 | 45 |
| Amitriptyline Hcl | Amitriptyline Hcl | 156 | 53 |
| Lisinopril | Lisinopril | 155 | 48 |
| Azithromycin | Azithromycin | 148 | 133 |
| Escitalopram Oxalate | Escitalopram Oxalate | 143 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 63 |
| Dutasteride | Dutasteride | 130 | 39 |
| Ozempic | Semaglutide | 130 | 29 |
| Ipratropium Bromide | Ipratropium Bromide | 127 | 54 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 122 | 37 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 119 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 116 | 49 |
| Celecoxib | Celecoxib | 113 | 39 |
| Meclizine Hcl | Meclizine Hcl | 113 | 54 |
| Mirtazapine | Mirtazapine | 112 | 34 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 109 | 40 |
| Paroxetine Hcl | Paroxetine Hcl | 108 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 16 |
| Farxiga | Dapagliflozin Propanediol | 99 | 25 |
| Methylprednisolone | Methylprednisolone | 99 | 90 |
| Risedronate Sodium | Risedronate Sodium | 99 | 40 |
| Alendronate Sodium | Alendronate Sodium | 93 | 26 |
| Topiramate | Topiramate | 92 | 27 |
| Xarelto | Rivaroxaban | 89 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 88 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 87 | 69 |
| Potassium Chloride | Potassium Chloride | 87 | 38 |
| Donepezil Hcl | Donepezil Hcl | 84 | 23 |
| Propranolol Hcl | Propranolol Hcl | 84 | 33 |
| Propranolol Hcl Er | Propranolol Hcl | 84 | 29 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 83 | 27 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 83 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 82 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 28 |
| Irbesartan | Irbesartan | 75 | 24 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 75 | 15 |
| Repaglinide | Repaglinide | 74 | 32 |
| Myrbetriq | Mirabegron | 73 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 48 |
| Clonidine Hcl | Clonidine Hcl | 72 | 23 |
| Prednisone | Prednisone | 70 | 41 |
| Trulicity | Dulaglutide | 68 | 14 |
| Synthroid | Levothyroxine Sodium | 67 | 22 |
| Fenofibrate | Fenofibrate,micronized | 66 | 22 |
| Colesevelam Hcl | Colesevelam Hcl | 65 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 18 |
| Lactulose | Lactulose | 61 | 40 |
| Fenofibrate | Fenofibrate Nanocrystallized | 60 | 16 |
| Cefuroxime | Cefuroxime Axetil | 59 | 53 |
| Atenolol | Atenolol | 57 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 54 | 17 |
| Fenofibrate | Fenofibrate | 51 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 15 |
| Jardiance | Empagliflozin | 50 | 15 |
| Clonazepam | Clonazepam | 48 | suppressed |
| Levetiracetam | Levetiracetam | 48 | 12 |
| Prolia | Denosumab | 48 | 29 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 48 | 17 |
| Eplerenone | Eplerenone | 47 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 47 | 46 |
| Pregabalin | Pregabalin | 47 | 12 |
| Rybelsus | Semaglutide | 47 | 13 |
| Methocarbamol | Methocarbamol | 46 | 18 |
| Mounjaro | Tirzepatide | 46 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 46 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 14 |
| Sotalol | Sotalol Hcl | 46 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 14 |
| Colestipol Hcl | Colestipol Hcl | 44 | 11 |
| Midodrine Hcl | Midodrine Hcl | 44 | suppressed |
| Primidone | Primidone | 44 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 44 | 29 |
| Lorazepam | Lorazepam | 43 | suppressed |
| Levofloxacin | Levofloxacin | 42 | 38 |
| Naltrexone Hcl | Naltrexone Hcl | 42 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 42 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 12 |
| Alprazolam | Alprazolam | 39 | 11 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 33 |
| Np Thyroid | Thyroid,pork | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 13 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Indapamide | Indapamide | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Nifedipine Er | Nifedipine | 27 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Colchicine | Colchicine | 26 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 25 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 25 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Dexamethasone | Dexamethasone | 23 | 16 |
| Ursodiol | Ursodiol | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 22 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 15 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Nystatin | Nystatin | 22 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Armour Thyroid | Thyroid,pork | 21 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 21 | suppressed |
| Rivastigmine | Rivastigmine | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 20 | suppressed |
| Acetazolamide | Acetazolamide | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Klor-Con 10 | Potassium Chloride | 17 | suppressed |
| Levoxyl | Levothyroxine Sodium | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Ondansetron Odt | Ondansetron | 15 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Mirabegron Er | Mirabegron | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | 13 |
| Torsemide | Torsemide | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Clonidine | Clonidine | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Silodosin | Silodosin | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $632.86 · 31 records | AstraZeneca Pharmaceuticals LP | BREZTRI, EVENITY, FARXIGA, JARDIANCE, KISUNLA, MAKO, MOUNJARO, NEXLETOL, NEXPLANON, OTEZLA, Ohtuvayre, PROLIA, REPATHA, REXULTI, ZENPEP, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error